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Context: Insulin-like Growth Factor (IGF) signaling is crucial for sex differentiation and development 
of Leydig and Sertoli cells in fetal mice testes. No such information is available for human embryonic 
and fetal testes and ovaries.  
Objective: To investigate presence and activity of the IGF signaling system during human embryonic 
and fetal ovarian and testicular development.  
Design: Human embryonic and fetal gonads were obtained following legal terminations of 
pregnancies. Gene expression was assessed by microarray and qPCR transcript analyses. Proteins of 
the IGF system components were detected with immunohistochemistry (IHC) and 
immunofluorescence (IF) analyses. Specimens were included between 2010-2017.  
Setting: University Hospital. 
Patients/Participants: Ovaries and testes from a total of 124 human embryos and fetuses aged 5-17 
post conception weeks (pcw) were obtained from healthy women aged 16-47 years resident in 
Denmark or Scotland.  
Main Outcome Measures: Gene expression analysis using microarray was performed in 46 
specimens and qPCR analysis in 56 specimens, both sexes included. Protein analysis included 22 
specimens (11 ovaries, 11 testes). 
Results: IGF system members were detected in embryonic and fetal testes and ovaries, both at gene 
transcript and protein level. A higher expression of IGF regulators was detected in testes than 






















Conclusions: These data indicate that the IGF system is active during very early gestation where it 
may have a regulatory role in Leydig cells.  

























The insulin-like growth factor (IGF) signaling system is a key mediator of cell growth, proliferation, 
survival and metabolism throughout the body (1–3). The ligands, IGF1 and IGF2, signal through the 
cell surface IGF receptors type 1 (IGFR1) and the insulin receptor (INSR) (4,5). Signal transduction is 
performed by the free ligand and the bioactivity of IGFs is tightly regulated by IGF binding proteins 
(IGFBP-1 to -6), that antagonize receptor binding, but prolong circulatory IGF half-life (6,7) (Fig. 1).  
 
 IGFs become bioactive when released from their binding proteins by different proteinases including 
Pregnancy-Associated Plasma Protein-A (PAPP-A) that specifically cleaves three of the six IGFBPs (i.e. 
IGFBP-2, IGFBP-4, and IGFBP-5) and secures release of IGFs in the vicinity of cell surface, close to the 
receptor (8–10). The proteolytic activity of PAPP-A is inhibited by stanniocalsin-1 and -2 (STC1, STC2), 
leading to downregulation of  IGF signaling (11,12) (Fig. 1). Information on the IGF system and its 
impact during embryonic and fetal development is primarily obtained from murine models. Mice 
deficient in Igf1r or Insr exhibit significant growth retardation and delay in sex differentiation 
(13,14). Moreover, sex reversal was observed in XY testes from Igf1r and Insr knockout mice, 
suggesting that IGF signaling is required for testis differentiation in mice (14,15). Reduced Sertoli cell 
proliferation and sperm production occurred when Igf1r and Insr were specifically inactivated in 
mouse Sertoli cells, emphasizing an important role of IGF signaling in Sertoli cell  proliferation and 
sperm production  in mice (16–18). The insulin receptor substrate (IRS) proteins are key mediators of 
insulin and insulin-like growth factor (IGF) signaling, and deletion of Irs2  causes reduced testicular 
weight, fewer, and abnormal, Sertoli  and sperm cells, indicating that Ins2 is vital for murine 
testicular development (19). Igf1 is expressed in testes of embryonic mice and Igf1 regulates somatic 
cell proliferation and promotes steroidogenesis, indicating that Igf1 is important for development of 






















indicated a vital role of Igf1 in mouse spermatogenesis, since it was found to decrease germ cell 
apoptosis and increase their density in culture (22).  
 
There is only limited information of the importance of IGF signaling during early development in 
humans. Neonatal testes show high expression levels of IGF2 and IGF1R  in Leydig cells, suggesting 
that IGF signaling  affects Leydig cell differentiation (23). IGF signaling has been reported to be 
essential for postnatal human testicular descent (24,25). Expression of IGF2 was decreased in both 
human testis and ovaries in midterm fetuses (26), although the expression was significantly higher in 
testes than ovaries This suggests that IGF2 expression is regulated differently in fetal testis than in 
ovaries and may exert a more pronounced function in testicular than ovarian development. IGF1 
expression has been detected in human fetal ovaries (15 and 22 post conception weeks (pcw)) (27), 
and may affect ovarian function during fetal life. In contrast, IGF2 is the primary ligand operating in 
adult human ovaries (28). In the adult human ovary, IGF signaling plays a significant role, regulating 
both folliculogenesis and steroidogenesis (29–32). 
In human adult testes, IGF1 has been detected in Sertoli and Leydig cells, and spermatocytes   
(33,34). The IGF1R is present on spermatocytes, early spermatids, and variably on Leydig cells, and 
may enhance spermatogenesis (33). Further, a positive correlation between IGF1 serum levels and 
testicular volume has been shown in pubertal boys, suggesting that IGF is involved in testicular 
growth (18,35).  
The aim of this study was to explore the expression of key regulators of the IGF signaling system in 
first and second trimester human embryonic and fetal gonads of both sexes, at both gene and 
protein levels. The study focuses on the changes in expression levels over time and the differences 
























Materials and Methods  
This study includes male and female gonads from a total of 124 first- and second-trimester human 
embryos and fetuses. Gene expression analysis was performed on RNA isolated from 46 embryonic 
and fetal gonads (18 ovaries, 28 testes) aged 5-9 post conception weeks (pcw) (mean ±SD; 7.7 weeks 
pc ±1.1), using a Human Transcriptome Array (HTA) 2.0 microarray analysis (36). Part of the data 
from the microarray analysis has previously been published (36). The gene expression assays were 
validated with qPCR using a total of 56 first and second trimester gonads (21 ovaries, 34 testes) aged 
5-18 pcw. Regulators of the IGF system were detected at protein level using immunohistochemistry 
(IHC) in a total of 22 first- and second trimester gonads (11 ovaries, 11 testes). Ovarian tissue 
sections with primordial follicles from one human ovary obtained from a 10.5-year-old girl with 
Fanconi anemia were used for positive controls. 
 
Participating women and ethical statement 
Participants were healthy women aged 16-47 years (mean age 24.3 years, 95% of the women 
were between 16 and 41, one woman was 47 years of age) enrolled in Denmark and Scotland, 
who underwent legal elective terminations of normally-progressing pregnancies under current 
legislation in each country (i.e. In Denmark before 10 pcw, in Scotland before 22 pcw). 
Women from Denmark were 18-47 years of age, women from Scotland were 16-33 years old. 
All participants received oral and written information about the study and gave their informed 
consent in writing prior to inclusion in the study. Exclusion criteria included dependence on 
an interpreter, chronic disease, and pregnancies with known disorders. In Denmark women 
below the age of 18 were also excluded. Participation had no effect on the medical care 






















regulations in Denmark and Scotland and was approved by the Scientific Ethical Committee 
for the Capital Region [KF(01)258206] and NHS Grampian Research Ethics Committees 
(REC 04/S0802/21, REC 15/NS/0123) respectively. Researchers have no access to patient 
identifiers and the women undergoing termination of pregnancy were therefore totally 
anonymized. The ovarian tissue cryopreservation scheme of the 10.5-year-old control patient 
with Fanconi anemia was approved by the Danish Ministry of Health (J. no. 30-1372) and by 
the Danish authorities to comply with the European Union tissue directive.  
 
Collection of human embryonic and fetal gonads 
Gonadal tissue from first- and second-trimester human embryos and fetuses from two separate 
collections were collected between 2010-2017. In Denmark, embryonic and fetal gonads were 
obtained following elective surgical terminations of pregnancies at Skejby University Hospital, 
Aarhus, Denmark as described previously (36). Second-trimester medically aborted samples were 
collected in Aberdeen, Scotland. Details on collection and cohort characteristics have previously 
been described (37,38).  
Gestational age was in all cases determined by crown-rump length (CRL) and head circumference 
(HC) for fetuses older than 14 pcw, using abdominal ultrasound. Gonads were identified and isolated 
using a stereomicroscope directly after the evacuation (Denmark) or dissected from intact fetuses 
(Scotland). Gonads obtained for gene expression analysis were snap-frozen on dry ice or placed in 
RNAlater® (Sigma-Aldrich, Copenhagen, Denmark) before frozen on dry ice and stored at -80°C until 
further analysis. Gonads obtained for IHC were fixed in Bouin’s solution or 4% neutral-buffered 
formaldehyde (NBF) and embedded in paraffin for histological analysis.  
All embryos and fetuses included in the study appeared morphologically normal. Embryonic and 
























Prior to RNA extraction whole human embryonic/fetal male and female gonads were homogenized 
on a TissueLyser II at 4°C (Qiagen) in 1.0mL TRI reagent® (cat. no. T9424, Sigma-Aldrich, Copenhagen, 
Denmark) for 2x30 second at 15 Hz, using 0.3mm stainless steel beads. Samples were further 
homogenized by adding 200 µl chloroform followed by 15 seconds shaking and incubation at room 
temperature for 2-3 min. The RNA was purified using silica membrane columns following the 
manufactured protocol (RNeasy Plus minikit, cat. no. 74136, Qiagen, Copenhagen, Denmark). 
 
Microarray analysis 
Gene expression data from the present microarray analysis related to sex differentiation has 
previously been published describing the microarray methods in detail (36). Gonadal RNA samples 
were amplified using an Ovation Pico WTA v.2 RNA amplification system according to the 
manufacturer’s instructions (Nugen, San Carlos, CA, USA) followed by cDNA synthesis using the 
Encore Biotin Module (Nugen, San Carlos, CA, USA) before hybridization to the HTA 2.0 GeneChip® 
(Affymetrix, Santa Clara, CA, USA). Using the Robust Multichip Average (RMA) and pre-filtering 
according to Bourgon and colleagues (40), the data was normalized as previously described (36). 
Log2 expression between 2.1 and 5 defined genes expressed in a compartment of cells and log2 
expression above 5 defined genes being expressed in either all cells or abundantly in a subset of 
cells. The probes identifying the IGF2 gene also covered exons including in the INS gene and the 
























Quantitative real-time PCR (RT-PCR) Analysis 
RNA from embryonic and fetal gonads was converted to first-strand cDNA by the use of the High 
Capacity cDNA Reverse Transcriptase Kit (Applied Biosystems, Carlsbad, CA, USA) according to the 
manufacturer’s instructions. Samples were kept on ice at all times. RT-PCR analysis was performed 
using TaqMan technology (Applied Biosystems), applying TaqMan Gene Expression Master Mix from 
Invitrogen (Invitrogen, 2012 Life Technologies Corporation) and predesigned Taq-Man Gene 
Expression Assays for the following genes: IGF2, IGFBP4, IGFBP5, STC1, STC2, and PAPP-A (probe-id: 
IGF2, Hs04188276_m1, Hs04188276_m1; IGFBP4, Hs01057900_m1; IGFBP5, Hs00181213_m1; STC1, 
Hs00174970_m1; STC2, Hs01063215_m1; PAPPA, Hs01032307_m1) (Invitrogen). The genes were 
selected based on their regulative role of IGF bioactivity. The cDNA samples were amplified in 
duplicates using the LightCycler 480 quantitative PCR instrument (Roche). Human glyceraldehyde 3-
phosphatdehydrogenase (GAPDH) was used as endogenous control (probe id. No.: 433764 F). All 
samples were normalized to GAPDH and the relative expression was quantified according to the 




Immunohistochemistry was performed on 5 μm paraffin-embedded sections, which were de-
paraffinized in xylene, gradually rehydrated in ethanol (99%, 96% and 70%) followed by antigen 
retrieval in either 10 mM sodium citrate, pH 6 or in 10 mM Tris, 0.5 mM EGTA, pH 9. Endogenous 
activity was inhibited using 3% peroxidase, followed by inhibition of nonspecific binding with 1% 
bovine serum albumin (BSA) (Sigma Aldrich, Copenhagen, Denmark). Sections were incubated with 
primary antibodies overnight at 4°C in a humid chamber; details of antibodies and conditions are 






















Denmark) and visualised with 3.3′-diaminobenzidine tetrahydrochloride (DAB+ Substrate 
Chromogen System, Dako). Both Universal negative control serum® (BioCare Medical, CA, USA) and 
antibody dilution buffer was used in place of primary antibody as IgG-negative controls and showed 
no staining in all specimens, data not shown.  
Immunofluorescence 
To investigate the localization of PAPP-A and the Leydig cell marker CYP17A1 immunofluorescence 
was performed. Briefly, 5 μm paraffin tissue sections were dewaxed in xylene and rehydrated in a 
graded ethanol series. Antigens were retrieved with Tris-EGTA buffer (10 mM Tris, 0.5 mM EGTA, pH 
9) boiled in a pressure cooker for 20 min. After cooling, slides were blocked in Tris-buffered saline 
(TBS) with 1% BSA (TBS: 50 mM Tris, 150 mM NaCl, pH 7.6) for 1 h prior to incubating with primary 
antibody (Table 1) at 4°C overnight. After incubation, slides were rinsed in TBS supplemented with 
Tween-20 (TBST) (100 mM Tris, 150 mM NaCl, 0.05% Tween-20, pH 7.6) and incubated with the 
appropriate secondary antibody for 1 h at room temperature. After rinse with TBST, slides were 
counterstained with DAPI (1:100) and mounted with Prolong Gold mounting medium (cat. No. 
P36930, Invitrogen). 
Statistical methods 
Statistical analyses of microarray and RT-PCR gene expression data were performed using a 
generalized linear model with a two-way interaction between embryonic/fetal sex and age. 
Normality checks were performed prior to each transcript data analysis. The potential for maternal 
age effects on RT-PCR gene expression profiles was analysed using the Pearson’s correlation model. 
For the purpose of this study, raw data were log2 transformed for consistency. Statistical 
significance was set to <0.05 and confidence intervals (CIs) at 95% were calculated and represented 
graphically. All statistical analyses and generation of graphs was performed using R Software version 

























Screening for IGF signaling family members 
Gene expressions in both ovaries and testes in relation to age (post conception days, pcd) are shown 
in Fig. 2. One-way interactions of expression with age for each sex separately and two-way 
interactions with age together with sex were checked for each presented gene. Expression of IGF1 
mRNA increased with age in both sexes, although only statistically significant in testes (p=0.013). No 
difference in expression was observed between the two sexes. In contrast, the INS-IGF2 expression 
(combined expression of insulin and IGF2) increased significantly with age in testis (p<0.001) and 
decreased in ovaries (p=0.002). The IGF1R showed similar expression patterns, with a lower 
expression in ovaries than testes, a   significant difference between the sexes was detected 
(p=0.044). Both IGF1R and INSR increase  significantly across gestation in testes (p<0.001, p<0.001), 
not in ovaries (p=0.869, p=0.865). All IGF binding proteins (IGFBPs) 1-6 were expressed in the first 
trimester gonads, with no significant difference in transcript levels between the sexes. The 
expression of IGFBP3 and IGFBP5 decreased significantly with age in both sexes (testes: p<0.001, 
p=0.003; ovaries: p=0.003, p=0.001) respectively, while no changes were observed according to age 
for other IGFBPs. PAPP-A and PAPPA-2 both significantly decreased with age in testes and ovaries 
(testes p<0.001, p<0.001; ovaries p=0.007, p=0.014), respectively. Overall, STC1 expression was 
higher than STC2 in both sexes. Only testicular STC1 expression increased significantly with age 
(p<0.001) but was significantly lower (p=0.014) than ovarian expression levels. There was no 
significant difference in the expression levels of STC2 between males and females. The downstream 
targets INSR, IRS1 and IRS2, were differentially expressed between the sexes. IRS1 was significantly 






















were also seen, with IRS1 expression significantly decreasing across gestation in ovaries (p<0.001) 
but not in testes, and IRS2 expression significantly increased with age in testes (p<0.001) but not in 
ovaries. Moreover, a significantly higher IRS2 expression was seen in testes from day 53 pc and 
onwards compared to before day 53 (p=0.01).  
 
Confirmation of IGF component transcripts in first and second trimester gonads 
A larger cohort of 34 male and 21 female gonads aged 5 to 17 pcw were used to perform RT-PCRs on 
IGF2, IGFBP4, PAPPA, STC1 and STC2 genes (Fig. 3). We observed no correlation between maternal 
age and any of the reported gene expression profiles (data not shown). As seen in the previous 
analysis, IGF2 expression increased in males and decreased in females across gestation, resulting in 
significant differential expression (p<0.001) between the two sexes.  However, the rate of change in 
expression across gestation was significant only for males (p=0.001). Expression of IGFBP4 decreased 
significantly across gestation in both sexes (p<0.001). A sex dimorphic expression pattern was 
observed for PAPP-A (p=0.030), with an increase in males and a decrease in females across 
gestation.  In testes, PAPP-A expression increased significantly with age (p=0.032), which was not the 
case in ovaries (p=0.3). Transcript levels for STC1 increased in males and decreased in females with 
significant sex (p<0.001) and age differences in both males (p<0.001) and females (p=0.006), in 
agreement with the microarray. The STC2 expression was higher in ovaries than testes confirming 
the microarray analysis. A significant decrease in STC2 expression across gestation was observed in 
























Immunohistochemical analysis  
Using immunohistochemistry, expression at the protein level of key IGF regulators (IGF1R, PAPPA, 
STC1, STC2, IGFBP-4 and IGFBP-5) in both testes and ovaries from pcw 5-18 was then assessed. 
Representative images are shown in Fig. 4. The analyses were performed in ovaries from consecutive 
pcw 6 and 8 to 18 representing all developmental weeks, except week 7. Testes included all pcw 6-
18. In testes, proteins of the IGF system localized primarily to Leydig cells although detection in germ 
and Sertoli cells was also observed (Fig. 4A). In contrast, proteins of the IGF system were generally 
expressed in both germ cells and somatic cells in the ovary, with no preference to a specific cell type 
(Fig. 4B). A tendency to a more intense straining to the germ cells was observed. 
 
PAPP-A in second trimester testis and ovary 
PAPP-A was detected in Leydig cells of a human male 17 pcw testis. Double staining with the Leydig 
cell marker CYP17 confirmed that PAPP-A was primarily located outside the seminiferous tubules 
with expression distinctly located to Ley ig cells (Fig. 5A). In the 18 pcw human fetal ovary, PAPP-A 
showed less specific localization. Double staining with the germ cell marker LIN28 revealed 

























This study describes, for the first time, expression of IGF system regulators in human ovaries and 
testes during embryonic and fetal life, at both gene and protein levels. These results demonstrate 
that IGF is potentially involved in gonadal growth and development as early as the embryonic stages 
around sex differentiation (6 pcw)  and onset of male steroidogenesis (8 pcw) (36,42). Moreover, the 
IGF signaling components increasing in expression with embryonic/fetal age (i.e. INS-IGF2, IGF1R, 
INSR, IRS2), were generally upregulated in testes compared to ovaries. In first trimester gonads, 
PAPP-A decreased with age in both sexes. Surprisingly, the expression in testes increased when 
specimens from both first and second trimester were included, indicating a biphasic PAPP-A 
expression pattern, with downregulation in the first trimester, while there is an upregulation in 
second trimester. Consequently, it may be hypothesized that bioavailable IGF2 is reduced in first 
trimester, with a relative increase in second trimester. Methodologically the array probe detecting 
IGF2 also included INS, whereas the qPCR probe detected IGF2 alone. Since the expression pattern 
obtained with the two different methods agreed, the contribution of INS to the array expression is 
probably minor. The IGF binding proteins remained constant between sexes across gestation in both 
sexes, while STC1, and STC2 were upregulated in ovaries compared to testes in first trimester 
specimens. Interestingly, the STC1 expression increased significantly in second trimester testes 
where the expression was higher than ovaries, illustrating a significant increased STC1 expression in 
testes across gestation. Collectively this suggests that the IGF system is a more central regulator in 
testes than in ovaries during embryonic and fetal development. This is interesting since there is 
hardly any circulation in embryos at these early developmental stages and suggests that IGF 
signaling occurs via para- and autocrine mechanisms in the developing gonads. Similarly, IGF 
signaling in the avascular human ovarian follicles has been described (28,43) emphasizing that active 
IGF signaling is not dependent on direct contact to the circulation. IGF1 was upregulated in both 
sexes across gestation, whereas IGF2 was upregulated in testes and downregulated in ovaries, 























Overall, there was good agreement between the two methods used for evaluating gonadal transcript 
expression of IGF signaling (i.e. microarray and qPCR analysis). The present study is retrospective and 
the functional role of the IGF system are not directly elucidated by these analyses. Further studies 
are needed to evaluate the precise regulatory effects that IGF signaling may exert on early fetal 
gonadal development as well as possible regulatory effects on the testicular steroidogenesis.   
 
Our findings confirm and extend the observations by Voutilainen and Miller, who, more than three 
decades ago, reported IGF2 to be expressed in human fetal gonads (13-26 gestational weeks) with a 
higher expression in testes than ovaries (26). While Voutilainen and Miller found a decrease in IGF2 
expression in testis from gestational week 13-26, we here show a significant increase from week 5-
16 pc, indicating that IGF2 may be a particularly important regulator during the crucial early events 
of sex differentiation and onset of steroidogenesis in males, which takes place in pcw 6 and 8, 
respectively (36,42). Taken together, this suggests that IGF signaling is relatively upregulated in the 
embryonic and fetal testes as compared to the ovary, indicating that IGF signaling may play a more 
important regulatory role in the developing testes than in the ovary. It adults the regulation of IGF 
signaling components change with age (44,45) and we tested whether maternal age was associated 
with the level of embryonic and fetal IGF gene expression, however, our data did not show any such 
associations.   
 
Our gene expression analyses revealed that both STC1 and STC2 and PAPP-A were expressed in 
testes and ovaries, indicating that proteinase-inhibitor complex formation is possible, and that PAPP-
A activity may be regulated by both STC1 and STC2. It has previously been shown in mice in vitro 






















and the inhibited complexes have been detected in human follicular fluids, demonstrating that 
complex formation occurs in adult human ovarian tissues, and suggesting that STC1 and STC2 
regulate PAPP-A in the adult human ovary during folliculogenesis (43). The present study detected a 
significant upregulation of STC1 transcript in testes across gestation, suggesting that PAPP-A may 
primarily be regulated by STC1 during first and second trimester.  
 
Gene expression of the intracellular IGF signaling mediators, IRS-1 and IRS-2, were detected in 
gonads of both sexes. Interestingly, IRS-1 expression was decreasing across gestation in ovaries and 
constantly expressed in testes while IRS-2 was increasing across gestation in testis and constantly 
expressed in ovaries. This indicates a sex dimorphic intracellular IGF signal transduction, with 
transduction increasing in testes and decreasing in ovaries with age. This illustrates that IGF 
regulation may be more critical in embryonic and fetal testis than in ovaries. IRS-2 increased 
significantly in testes from day 53 and onwards compared to the levels before day 53, which 
correlates exactly with the previously reported onset of human steroidogenic onset around day 53 
pc (36). This supports the hypothesis that IGF mediated signaling may affect steroidogenesis in 
human fetal Leydig cells, as seen in human postnatal Leydig cells (23). In the adult human testis both 
IRS-1 and IRS-2 have been detected. Furthermore, IRS-1 has been detected in peritubular myoid cells 
and interstitial cells, which is in accordance with the high energy expenditure of these contractile 
cells in the adult testis (46). Irs-2is required for normal testis development in mice. Contradictorily, 
Irs-2 deficient mice present with abnormalities in Sertoli cells and germ cells rather than in Leydig 
cells (19), indicating that IGF regulation is likely to be different between the two species. However, 
Irs-2 has been detected in Sertoli cells, germ cells, and Leydig cells in adult rat testes, suggesting that 























Our immunohistochemical analysis showed that all evaluated components of the IGF system were 
present at protein level in both testes and ovaries. Furthermore, in testes, the IGF components 
located primarily to Leydig cells, which implies that IGF signaling may exert functions in different cell 
compartments at various time points as well as a sex specific role in regulating fetal Leydig cells 
differentiation and steroidogenesis. PAPP-A and CYP17A1 (a key enzyme in androgen synthesis) 
were also located specifically to embryonic/fetal human Leydig cells, further supporting the 
hypothesis that IGF signaling may affect early steroidogenesis. These observations confirm a 
previous report, which also detected IGF-2, IGF1R and INSR primarily located to Leydig cells in 
postnatal human testes and implied that IGF signaling was involved in postnatal human testicular 
differentiation and steroidogenesis (23). The present study found that both IGF-1 and IGF-2 are 
expressed in embryonic and fetal testis. Previous studies have reported that serum IGF-1 levels 
correlate with testes size in children and adolescents (35) and that adult human Leydig cells, Sertoli 
cells, and spermatocytes express IGF-1 (33). One study found IGF-2 expressed in spermatocytes and 
in some Sertoli cells in adult testicular tissue (47). Further, IGF-2 correlated with the FSH receptor 
(FSHR) expression, implicating a paracrine control of spermatogenesis (47). A potential different 
regulation and function of IGFs fetal gonads than in adults require further studies to elucidate.  
 
In summary, our data provide the first evidence that the IGF signaling system is active in human 
embryonic and fetal gonads of both sexes, with a relatively higher expression of most components in 
testes compared to ovaries. The IGF components were located primarily to Leydig cells in testis, 

























First and second trimester specimens were collected in Denmark and Scotland, respectively and 
geographical differences in maternal lifestyles which potentially could affect results cannot be 
excluded. There were no obvious differences between the Danish and Scottish participants regarding 
age, BMI, and rural/urban site of living. All analyses were performed in Denmark in order to maintain 
methodological consistency. Moreover, the data is descriptive and further studies are required for 
mechanistic conclusions.    
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Figure legends:  
Figure 1. Regulation of IGF signaling and the inhibitory effects of stanniocalsin (STC). IGFs are 
tightly regulated by IGF binding proteins (IGFBPs) that inhibit receptor binding. PAPPA-A cleaves 
IGFBPs causing release of bioactive IGF, which binds to the receptors IGF1R or INSR and induces 
intracellular signaling mediated by IRS1 and IRS2. IGF signaling is downregulated by STCs inhibiting 
PAPP-A. GAG – Glycosaminoglycan.  
Figure 2. Effects of fetal age and sex on IGF signalling pathway members. Data was from microarray analysis of 
18 ovaries (42-64 pcd) and 28 testes (40-68 pcd). Black arrows above graphs indicate a two-way significant 
interaction between sex, age and expression levels. Shading illustrate 95% confidence intervals. Pcd=post 
conception days 
 
Figure 3. Confirmation of microarray findings for a larger populatio . Relative transcript levels from q-PCR 
analysis of 21 ovaries (42-133 pcd) and 34 testes (35-126 pcd) are shown. Black arrows above graphs indicate a 
two-way significant interaction between sex, age and expression levels. Shading indicate 95% confidence 
intervals. Pcd= post conception days 
 
Figure 4. Localization of IGF1R, IGFBP4, IGFBP5, PAPP-A, STC1, and STC2 in embryonic and fetal testes (A) and 
ovaries (B).The components were located primarily in the Leydig cells in testes, with a weak detection in germ 
and Sertoli cells, whereas a general expression was seen in the ovary, with a prevalence to germ cells. Scale 
bars: fetal gonads=50 µm, primordial follicle=20 µm. 
 
Figure 5.  Fluorescent staining of A) PAPP-A together with the Leydig cell marker CYP17 in 17 pcw testis. White 
arrows indicate Leydig cell staining. PAPP-A was localized in Leydig cells and there was no protein presence 
within the seminiferous tubules. B) PAPP-A and the germ cell marker LIN28 in an 18 pcw fetal ovary. White 
arrows indicate a cluster of germ cells. There was a more global localization of PAPP-A in the ovary. PAPP-A was 


























Table 1. Antibody information  
Antibody Species Supplier Cat. No. Concentration  Dilution 
IGF1R Rabbit Cell Signaling Technologya 3027S 2.6 µg/mL 1:50 
PAPP-A Mouse Giftb - 6.4 µg/mL 1:100 
STC1 Mouse Giftb - 2.3 µg/mL 1:300 
STC2 Mouse Giftb - 2.5 µg/mL 1:400 
IGFBP4 Mouse Giftb - 10 µg/mL 1:100 
IGFBP5 Mouse Giftb - 6.3  µg/mL 1:300 
CYP17A1 Mouse Santa Cruzc Sc-374244 2  µg/mL 1:100 
LIN28 Rabbit Abcamd Ab46020 10 µg/mL 1:100 
 
a BioNordika Denmark A/S, Herlev, Denmark 
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